# TWO DECADES OF TRANSFORMATION UNDER MILES WHITE

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1999 | - Miles D. White takes over as Abbott chairman and CEO. The company serves customers in 130 countries, has approximately 57,000 employees, sales of $12.5 billion with more than 60% in the U.S., and a market capitalization of $75 billion.  
- Acquires Perclose, providing the foundation for building the company’s leading cardiovascular business. |
| 2000 | - Begins unique public-private partnership in Tanzania to strengthen the country’s healthcare system, investing more than $130 million during the next two decades. The partnership strengthens treatment and care, including a modern ER that decreased hospital mortality rates by 40 percent. |
| 2001 | - Acquires Knoll Pharmaceuticals, jump-starting the company’s portfolio and pipeline. Abbott developed and launched Humira®, which would become the world’s leading drug. |
| 2003 | - Establishes Point-of-Care business, enabling rapid, near-patient testing, with the acquisition of i-STAT. |
| 2004 | - Spins off the hospital products business as Hospira, an independent, publicly traded company. Pfizer later buys Hospira for $17 billion in 2015.  
- Acquires TheraSense, a leading blood-glucose monitoring business, setting the stage for what is now a market-leading diabetes care business. |
| 2005 | - Earns place on the Dow Jones Sustainability Index, one of the most prestigious benchmarks for sustainable, responsible business practices; company has remained on list for 19 years, leading the healthcare industry for the past seven years. |
| 2006 | - Acquires Guidant’s vascular business, further expanding the company’s growing medical device and heart care businesses through leading products like the XIENCE drug-eluting stent.  
- Creates fully-integrated global nutrition business. Sales of its international division have nearly tripled to $4.2 billion since its formation. |
| 2010 | - Acquires Solvay’s pharmaceutical business, providing a diverse branded generics portfolio and significant presence in key emerging markets.  
- Forms a stand-alone Established Pharmaceuticals business, a unique model in the industry focused solely on providing branded generic medicines in emerging markets.  
- Acquires Piramal’s Healthcare Solutions business in India, bolstering Abbott’s branded generics business by making it a leader in the large Indian pharmaceutical market. |
| 2013 | - Separates its research-based pharmaceutical business into a new public company called AbbVie. Today, the combined market capitalization of the companies has risen 167% to $277 billion.  
- FreeStyle Libre®, the world’s first continuous glucose-monitoring system (CGM) to eliminate fingersticks, is approved in Europe. It was later approved for use in the U.S. and is the No. 1 CGM in the world. |
| 2014 | - Expands Established Pharma business with the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia, further enhancing its presence in fast-growing markets. |
| 2016 | - Launches Alinity™, a family of six diagnostics systems, across all of Abbott’s laboratory testing segments, marking an unprecedented reimagination of the testing platforms for the company and the industry. |
| 2017 | - Acquires St. Jude Medical, creating a medical device leader with top positions in high-growth cardiovascular markets and a leader in neuromodulation to treat chronic pain and movement disorders.  
- Creates the world’s leading point-of-care diagnostics business through the acquisition of Alere. |
| 2019 | - Ranks No. 1 in its industry among Fortune’s Most Admired companies for the sixth straight year. Abbott is one of 52 from the original Fortune 500 and just 59 from the initial S&P 500 to remain on those lists.  
- Abbott’s stock reaches all-time high. Mr. White has created $220 billion in shareholder value and a total return of 575%, well ahead of the Dow Jones Industrial Average (393%) and S&P 500 (274%) over the same timeframe.  
- Abbott’s sales have grown to $30.6 billion today with 65% in international markets and a market cap of $149 billion (excluding AbbVie and Hospira). The company now has 103,000 employees serving people in more than 160 countries. |

1 Humira® is a registered trademark of AbbVie, Inc.  
2 Includes the combined market capitalization of Abbott, AbbVie and Hospira ($294 billion)